Evidence map›Paper›PMID 41236163›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Prickle4 Drives Microenvironmental Remodeling and Resistance to Parp Inhibition in IDH-Mutant Glioma.

Ju Yang, Hua Yang, Yifan Yuan, Chenyang Zhang, Ziwei Fu, Yanyan Chen, Yinghong Xiong, Shuyu Chen, Kexin Ling, Ying Liu and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Ju YangDepartment of Pathology, School of Basic Medical Sciences, Shanghai Fifth People's Hospital, Fudan University, Shanghai, 200040, China.
Hua YangDepartment of Pathology, School of Basic Medical Sciences, Fudan University, Shanghai, 200040, China.
Yifan YuanDepartment of Neurosurgery, National Center for Neurological Disorders, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Chenyang ZhangDepartment of Pathology, School of Basic Medical Sciences, Fudan University, Shanghai, 200040, China.
Ziwei FuDepartment of Pathology, School of Basic Medical Sciences, Fudan University, Shanghai, 200040, China.
Yanyan ChenDepartment of Pathology, School of Basic Medical Sciences, Fudan University, Shanghai, 200040, China.
Yinghong XiongDepartment of Pathology, School of Basic Medical Sciences, Fudan University, Shanghai, 200040, China.
Shuyu ChenDepartment of Pathology, School of Basic Medical Sciences, Fudan University, Shanghai, 200040, China.
Kexin LingDepartment of Pathology, School of Basic Medical Sciences, Fudan University, Shanghai, 200040, China.
Ying LiuDepartment of Pathology, School of Basic Medical Sciences, Fudan University, Shanghai, 200040, China.
Jason T HuseDepartments of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Bo ChenKeymed Biosciences (Chengdu) Limited, Chengdu, Sichuan, 610219, China.
Timothy A ChanCenter for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, Ohio, 44195, USA.
Zengxin QiDepartment of Neurosurgery, National Center for Neurological Disorders, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Zhao ZhangMOE Key Laboratory of Metabolism and Molecular Medicine, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, 200040, China.
Xiuping LiuDepartment of Pathology, School of Basic Medical Sciences, Shanghai Fifth People's Hospital, Fudan University, Shanghai, 200040, China.
Yuxiang WangDepartment of Pathology, School of Basic Medical Sciences, Fudan University & Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, 200032, China.ORCID https://orcid.org/0000-0002-1261-3985

Funding

National Major Science and Technology Projects of China 2023ZD0511800National Natural Science Foundation of China 32270708 82203195
6 · The paper itself

Abstract

Mutations in isocitrate dehydrogenase (IDH) genes sensitize gliomas to PARP inhibition (PARPi) by inducing epigenetic reprogramming of DNA damage repair circuits. However, tumors treated with PARPi eventually relapse despite initial responsiveness. In this study, it is demonstrated that the anti-angiogenic agent lenvatinib synergizes effectively with PARPi, resulting in substantial tumor regression and significantly extended survival. Genomic analysis of tumors reveals that PARPi induces widespread transcriptomic changes that are predominantly pro-inflammatory, thereby promoting tumor angiogenesis. Prickle4, a planar cell polarity protein, is identified as a critical mediator of PARPi-induced neovascularization. Targeting Prickle4 effectively overcomes PARPi resistance in these tumors. Collectively, these findings identified the Prickle4-mediated microenvironmental remodeling as the key resistance mechanism to PARPi, and support the therapeutic promise of multimodal therapy combining PARPi with anti-angiogenic agents for glioma treatment.

Indexed as

Brain NeoplasmsDrug Resistance, NeoplasmGliomaIsocitrate DehydrogenasePoly(ADP-ribose) Polymerase InhibitorsTumor MicroenvironmentAnimalsCell Line, TumorHumansMiceMutationNeovascularization, PathologicIsocitrate DehydrogenasePoly(ADP-ribose) Polymerase InhibitorsangiogenesisgliomaIDHPARP

Identifiers

PMID41236163
PMCPMC12806547

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.